Summary
Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
- The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects
- The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc.
AnGes MG, Inc.
Angion Biomedica Corp.
ARCA biopharma, Inc.
Ascelegen Therapeutics, Inc.
Asklepios BioPharmaceutical, Inc.
Asterias Biotherapeutics, Inc.
Athersys, Inc.
Bayer AG
BEAT BioTherapeutics Corp.
BioCardia, Inc.
Bristol-Myers Squibb Company
Capricor Therapeutics, Inc.
Celyad SA
FibroGen, Inc.
GlaxoSmithKline Plc
Glucox Biotech AB
Heart Metabolics Limited
Hemostemix Ltd
Innopharmax Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Juventas Therapeutics, Inc.
La Jolla Pharmaceutical Company
Laboratoires Pierre Fabre SA
Lee's Pharmaceutical Holdings Limited
Les Laboratoires Servier SAS
Lonestar Heart, Inc.
Mast Therapeutics, Inc.
Merck & Co., Inc.
Mesoblast Limited
MI.TO. Technology S.r.L.
miRagen Therapeutics, Inc.
Novartis AG
Nuo Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Palatin Technologies, Inc.
Pfizer Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Quantum Genomics SA
Recardio GmbH
RedHill Biopharma Ltd.
Sanofi
Stealth BioTherapeutics Inc.
Stemedica Cell Technologies, Inc.
Target Heart Biotec Srl
Theravance Biopharma, Inc.
TiGenix NV
Torrent Pharmaceuticals Limited
Trevena, Inc.
U.S. Stem Cell, Inc.
UniQure N.V.
Vichem Chemie Research Ltd.
Vicore Pharma AB
Zensun (Shanghai) Sci & Tech Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Congestive Heart Failure (Heart Failure) Overview 11
Therapeutics Development 12
Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 12
Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 13
Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 14
Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 20
Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Congestive Heart Failure (Heart Failure) - Products under Development by Companies 25
Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 32
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 34
Amgen Inc. 34
AnGes MG, Inc. 35
Angion Biomedica Corp. 36
ARCA biopharma, Inc. 37
Ascelegen Therapeutics, Inc. 38
Asklepios BioPharmaceutical, Inc. 39
Asterias Biotherapeutics, Inc. 40
Athersys, Inc. 41
Bayer AG 42
BEAT BioTherapeutics Corp. 43
BioCardia, Inc. 44
Bristol-Myers Squibb Company 45
Capricor Therapeutics, Inc. 46
Celyad SA 47
FibroGen, Inc. 48
GlaxoSmithKline Plc 49
Glucox Biotech AB 50
Heart Metabolics Limited 51
Hemostemix Ltd 52
Innopharmax Inc. 53
Jiangsu Hengrui Medicine Co., Ltd. 54
Juventas Therapeutics, Inc. 55
La Jolla Pharmaceutical Company 56
Laboratoires Pierre Fabre SA 57
Lee's Pharmaceutical Holdings Limited 58
Les Laboratoires Servier SAS 59
Lonestar Heart, Inc. 60
Mast Therapeutics, Inc. 61
Merck & Co., Inc. 62
Mesoblast Limited 63
MI.TO. Technology S.r.L. 64
miRagen Therapeutics, Inc. 65
Novartis AG 66
Nuo Therapeutics, Inc. 67
Ono Pharmaceutical Co., Ltd. 68
Palatin Technologies, Inc. 69
Pfizer Inc. 70
PharmaIN Corporation 71
PhaseBio Pharmaceuticals, Inc. 72
Pluristem Therapeutics Inc. 73
Quantum Genomics SA 74
Recardio GmbH 75
RedHill Biopharma Ltd. 76
Sanofi 77
Stealth BioTherapeutics Inc. 78
Stemedica Cell Technologies, Inc. 79
Target Heart Biotec Srl 80
Theravance Biopharma, Inc. 81
TiGenix NV 82
Torrent Pharmaceuticals Limited 83
Trevena, Inc. 84
U.S. Stem Cell, Inc. 85
UniQure N.V. 86
Vichem Chemie Research Ltd. 87
Vicore Pharma AB 88
Zensun (Shanghai) Sci & Tech Co., Ltd. 89
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 90
Assessment by Monotherapy Products 90
Assessment by Combination Products 91
Assessment by Target 92
Assessment by Mechanism of Action 97
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 105
(sacubitril + valsartan) - Drug Profile 105
AAVS-100A1 - Drug Profile 108
ACP-01 - Drug Profile 109
AdipoCell - Drug Profile 111
AdipoCell + MyoCell - Drug Profile 113
aladorian sodium - Drug Profile 114
ALD-201 - Drug Profile 116
AMG-986 - Drug Profile 117
ANG-4011 - Drug Profile 118
AntimiR-199a - Drug Profile 119
ARX-720 - Drug Profile 120
BAY-1067197 - Drug Profile 121
BBR-12 - Drug Profile 122
beperminogene perplasmid - Drug Profile 123
BNP-CHF - Drug Profile 128
bucindolol hydrochloride - Drug Profile 129
C-21 - Drug Profile 132
C3BSCQR-1 - Drug Profile 134
CAP-1002 - Drug Profile 136
carvedilol CR - Drug Profile 138
carvedilol phosphate CR - Drug Profile 139
cenderitide - Drug Profile 140
CLR-325 - Drug Profile 142
CM-1 - Drug Profile 143
CTX-101 - Drug Profile 145
CXL-1036 - Drug Profile 147
CXL-1427 - Drug Profile 148
Drug for Heart Failure - Drug Profile 149
Drug to Inhibit Calpain for Heart Failure - Drug Profile 150
Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile 151
Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 152
ECR-A1 - Drug Profile 153
elamipretide - Drug Profile 154
enalapril maleate - Drug Profile 156
F-373280 - Drug Profile 157
FG-6874 - Drug Profile 158
FG-8205 - Drug Profile 159
finerenone - Drug Profile 160
furosemide - Drug Profile 161
GDF-11 - Drug Profile 162
Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 163
Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 164
Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 165
Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 166
Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 167
GSK-2798745 - Drug Profile 168
istaroxime - Drug Profile 169
ITD-1 - Drug Profile 171
ivabradine hydrochloride - Drug Profile 172
ivabradine hydrochloride SR - Drug Profile 173
JVS-100 - Drug Profile 174
KBP-5074 - Drug Profile 176
MGN-9103 - Drug Profile 177
milrinone ER - Drug Profile 178
MP-3167 - Drug Profile 179
MPC-150IM - Drug Profile 181
MyoCell - Drug Profile 183
MyoCell SDF-1 - Drug Profile 184
Neucardin - Drug Profile 185
NM-922 - Drug Profile 187
Oligonucleotides for Heart Failure - Drug Profile 188
omecamtiv mecarbil MR - Drug Profile 189
ONO-4232 - Drug Profile 192
PB-1046 - Drug Profile 193
Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 195
perhexiline maleate - Drug Profile 196
PF-05285401 - Drug Profile 198
PHIN-1138 - Drug Profile 203
PL-3994 - Drug Profile 204
PLX-PAD - Drug Profile 206
poloxamer - Drug Profile 210
pyroglutaminated serpinin - Drug Profile 212
QGC-101 - Drug Profile 213
REC-02 - Drug Profile 214
Recombinant Protein for Congestive Heart Failure - Drug Profile 215
rivaroxaban - Drug Profile 216
RT-100 - Drug Profile 222
RT-110 - Drug Profile 223
RT-210 - Drug Profile 224
S-38844 - Drug Profile 225
SAR-296968 - Drug Profile 226
serelaxin - Drug Profile 227
serpinin - Drug Profile 230
SG-1002 - Drug Profile 231
sildenafil citrate - Drug Profile 233
Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 235
Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 236
Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile 237
Small Molecules for Chronic Heart Failure - Drug Profile 238
Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 239
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 240
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 241
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 242
Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 243
Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 244
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 245
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Heart Failure and Metabolic Syndrome - Drug Profile 246
Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 247
sodium nitrite - Drug Profile 248
SP-20202 - Drug Profile 250
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 251
Stem Cell Therapy for Heart failure - Drug Profile 253
Stem Cell Therapy for Heart Failure - Drug Profile 254
Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile 255
Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 257
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 258
TD-0714 - Drug Profile 259
TR-4 - Drug Profile 260
TRC-4186 - Drug Profile 261
TRV-027 - Drug Profile 263
TRV-120023 - Drug Profile 265
ularitide - Drug Profile 266
vepoloxamer - Drug Profile 267
vericiguat - Drug Profile 269
XC-002 - Drug Profile 270
Xcel-hCardP - Drug Profile 271
XEN-105 - Drug Profile 272
Congestive Heart Failure (Heart Failure) - Recent Pipeline Updates 273
Congestive Heart Failure (Heart Failure) - Dormant Projects 367
Congestive Heart Failure (Heart Failure) - Discontinued Products 377
Congestive Heart Failure (Heart Failure) - Product Development Milestones 379
Featured News & Press Releases 379
Appendix 387
Methodology 387
Coverage 387
Secondary Research 387
Primary Research 387
Expert Panel Validation 387
Contact Us 387
Disclaimer 388
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016 21
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 24
Number of Products under Development by Companies, H1 2016 (Contd..1) 25
Number of Products under Development by Companies, H1 2016 (Contd..2) 26
Number of Products under Development by Companies, H1 2016 (Contd..3) 27
Number of Products under Development by Companies, H1 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Development, H1 2016 32
Comparative Analysis by Unknown Stage Development, H1 2016 33
Products under Development by Companies, H1 2016 34
Products under Development by Companies, H1 2016 (Contd..1) 35
Products under Development by Companies, H1 2016 (Contd..2) 36
Products under Development by Companies, H1 2016 (Contd..3) 37
Products under Development by Companies, H1 2016 (Contd..4) 38
Products under Development by Companies, H1 2016 (Contd..5) 39
Products under Development by Companies, H1 2016 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2016 41
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 42
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H1 2016 43
Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H1 2016 44
Congestive Heart Failure (Heart Failure) - Pipeline by Angion Biomedica Corp., H1 2016 45
Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H1 2016 46
Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H1 2016 47
Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 48
Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 49
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H1 2016 50
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2016 51
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H1 2016 52
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H1 2016 53
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2016 54
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H1 2016 55
Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H1 2016 56
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H1 2016 57
Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2016 58
Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H1 2016 59
Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H1 2016 60
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H1 2016 61
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H1 2016 62
Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 63
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H1 2016 64
Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2016 65
Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 66
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 67
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2016 68
Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H1 2016 69
Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H1 2016 70
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H1 2016 71
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H1 2016 72
Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H1 2016 73
Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H1 2016 74
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2016 75
Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H1 2016 76
Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 77
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H1 2016 78
Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H1 2016 79
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H1 2016 80
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 81
Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H1 2016 82
Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H1 2016 83
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2016 84
Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H1 2016 85
Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2016 86
Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H1 2016 87
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 88
Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2016 89
Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H1 2016 90
Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2016 91
Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 92
Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H1 2016 93
Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H1 2016 94
Congestive Heart Failure (Heart Failure) - Pipeline by UniQure N.V., H1 2016 95
Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H1 2016 96
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2016 97
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 98
Assessment by Monotherapy Products, H1 2016 99
Assessment by Combination Products, H1 2016 100
Number of Products by Stage and Target, H1 2016 102
Number of Products by Stage and Mechanism of Action, H1 2016 107
Number of Products by Stage and Route of Administration, H1 2016 111
Number of Products by Stage and Molecule Type, H1 2016 113
Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H1 2016 282
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2016 376
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H1 2016 377
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H1 2016 378
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H1 2016 379
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H1 2016 380
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H1 2016 381
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H1 2016 382
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H1 2016 383
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H1 2016 384
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H1 2016 385
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2016 386
Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H1 2016 387
List of Figures
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016 21
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Products, H1 2016 32
Assessment by Monotherapy Products, H1 2016 99
Assessment by Combination Products, H1 2016 100
Number of Products by Top 10 Targets, H1 2016 101
Number of Products by Stage and Top 10 Targets, H1 2016 101
Number of Products by Top 10 Mechanism of Actions, H1 2016 106
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 106
Number of Products by Top 10 Routes of Administration, H1 2016 110
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 110
Number of Products by Top 10 Molecule Types, H1 2016 112
Number of Products by Stage and Top 10 Molecule Types, H1 2016 112
